Associated Papers
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
40437208 (PubMed )
Supplement: 43856_2025_921_MOESM4_ESM.xlsx › Blad1
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M et al.
Translational Lung Cancer Research, 2025
40386732 (PubMed )
Supplement: tlcr-14-04-1254-supplementary.pdf
Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Lin CW et al.
Oncology Letters, 2025
39807107 (PubMed )
Supplement: Supplementary_Data2.pdf
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
Highly Sensitive 3D-Nanoplasmonic-Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy.
Lee JY et al.
Small Science, 2024
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
39063150 (PubMed )
Supplement: ijms-25-07908-s001.zip › ijms-3103240-supplementary.pdf
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Akkhasutthikun P et al.
Cancer Research and Treatment, 2024
37986562 (PubMed )
Supplement: crt-2023-1108-Supplementary-Table-S10.pdf
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A et al.
Cancer Medicine, 2024
38457233 (PubMed )
Supplement: CAM4-13-e7077-s003.xlsx › Table_S5
Evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer.
Xu Y et al.
Journal of Thoracic Disease, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM5_ESM.xlsx › combie_list
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer.
Park IH et al.
Cancer Research and Treatment, 2024
37340844 (PubMed )
Supplement: crt-2023-408_S1_Table.pdf
Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR.
Léonce C et al.
International Journal of Molecular Sciences, 2023
37958668 (PubMed )
Supplement: ijms-24-15684-s001.zip › ijms-2676079_-_Supplementary_Figures_S1-S5.pdf
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV et al.
International Journal of Molecular Sciences, 2023
37686200 (PubMed )
Supplement: ijms-24-13390-s001.zip › ijms-2558089-supplementary.pdf
Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T et al.
Scientific Reports, 2023
37612335 (PubMed )
Supplement: 41598_2023_40271_MOESM1_ESM.pdf
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
37047382 (PubMed )
Supplement: ijms-24-06410-s001.zip › ijms-2177723-supplementary.pdf
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
36128861 (PubMed )
Supplement: jptm-2022-06-11-suppl1.pdf
The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors.
Lee H et al.
Cancers, 2022
35740676 (PubMed )
Supplement: cancers-14-03011-s001.zip › cancers-1735308-supplementary.pdf
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
35627184 (PubMed )
Supplement: genes-13-00799-s001.zip › genes-1613678-supplementary.pdf
PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J et al.
Frontiers in Medicine, 2022
35308511 (PubMed )
Supplement: Table_1.XLSX › Sheet1
Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions.
González de Aledo-Castillo JM et al.
Diagnostics (basel, Switzerland), 2021
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
Ntzifa A et al.
Cancers, 2021
34073111 (PubMed )
Supplement: cancers-13-02736-s001.zip › cancers-1192044-supplementary.pdf
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z et al.
Cancer Medicine, 2021
33932095 (PubMed )
Supplement: CAM4-10-3323-s001.docx
Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.
Garcia J et al.
Molecular Diagnosis & Therapy, 2021
33660188 (PubMed )
Supplement: 40291_2021_515_MOESM1_ESM.pdf
Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
Song X et al.
British Journal of Cancer, 2020
32782293 (PubMed )
Supplement: 41416_2020_1024_MOESM1_ESM.pdf
Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate.
Arcila ME et al.
Jto Clinical and Research Reports, 2020
33511359 (PubMed )
Supplement: mmc1.docx
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S et al.
Expert Review of Molecular Diagnostics, 2020
Rapid EGFR mutation testing in lung cancer tissue samples using a fully automated system and single-use cartridge.
Al-Turkmani MR et al.
Practical Laboratory Medicine, 2020
Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM et al.
The Journal of Molecular Diagnostics : Jmd, 2019
Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients.
Castellanos-Rizaldos E et al.
Oncotarget, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
30064409 (PubMed )
Supplement: 12894_2018_380_MOESM1_ESM.xlsx › Supplementary_Table_1
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
29161613 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.
Su J et al.
Oncotarget, 2017
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
29141884 (PubMed )
Supplement: aan6566_supplementary_tables.zip › aan6566_Table_S2.xlsx › Table_S2
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U et al.
Expert Review of Molecular Diagnostics, 2017
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y et al.
Oncotarget, 2017
28107191 (PubMed )
Supplement: oncotarget-08-15023-s001.pdf
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma.
Xu T et al.
Theranostics, 2017
28529628 (PubMed )
Supplement: thnov07p1437s1.pdf
Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population.
Trachu N et al.
Oncotargets and Therapy, 2017
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH et al.
Expert Review of Molecular Diagnostics, 2016
A primer and probe set for detecting multiple types of EGFR exon 19 deletions.
Chen TL et al.
Analytical Biochemistry, 2016
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients.
Hsu KH et al.
Oncotarget, 2016
27449093 (PubMed )
Supplement: oncotarget-07-53299-s001.pdf
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS et al.
Oncotarget, 2016
27384480 (PubMed )
Supplement: oncotarget-07-48059-s001.pdf
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
26527317 (PubMed )
Supplement: oncotarget-06-43731-s002.xlsx › Table_S1
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
26009992 (PubMed )
Supplement: oncotarget-06-24499-s002.xlsx › Supplementary_Table_1
Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients.
Bichev SN et al.
Cellular Oncology (dordrecht, Netherlands), 2015
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M et al.
Pathology, 2014
Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY et al.
Lung Cancer (amsterdam, Netherlands), 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Tseng JS et al.
Plos One, 2014
25215536 (PubMed )
Supplement: pone.0107160.s001.pdf
1–50 of 57 papers
Select a paper to view details